Jasper Therapeutics (NASDAQ:JSPR) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Jasper Therapeutics (NASDAQ:JSPR) in a report released on Monday, Benzinga reports. The firm currently has a $65.00 price objective on the stock.

A number of other equities research analysts have also recently commented on the company. Stifel Nicolaus assumed coverage on Jasper Therapeutics in a research note on Thursday, June 27th. They issued a buy rating and a $86.00 target price on the stock. Cantor Fitzgerald reissued an overweight rating on shares of Jasper Therapeutics in a research note on Tuesday, June 18th. Finally, BTIG Research assumed coverage on Jasper Therapeutics in a research note on Monday, July 8th. They issued a buy rating and a $90.00 target price on the stock. Eleven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of Buy and a consensus price target of $69.56.

Jasper Therapeutics Trading Up 0.6 %

JSPR traded up $0.10 during trading on Monday, reaching $16.62. The stock had a trading volume of 141,445 shares, compared to its average volume of 133,885. The stock’s 50 day moving average is $22.14 and its two-hundred day moving average is $21.97. The company has a market capitalization of $250.36 million, a price-to-earnings ratio of -2.95 and a beta of 2.21. Jasper Therapeutics has a one year low of $4.00 and a one year high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.23. On average, equities research analysts predict that Jasper Therapeutics will post -4.41 earnings per share for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

Several institutional investors have recently modified their holdings of JSPR. Fernwood Investment Management LLC boosted its position in shares of Jasper Therapeutics by 8.8% during the fourth quarter. Fernwood Investment Management LLC now owns 494,706 shares of the company’s stock valued at $390,000 after buying an additional 40,000 shares during the last quarter. Monaco Asset Management SAM bought a new position in Jasper Therapeutics in the fourth quarter valued at about $197,000. Ieq Capital LLC bought a new position in Jasper Therapeutics in the fourth quarter valued at about $43,000. Opaleye Management Inc. bought a new position in Jasper Therapeutics in the fourth quarter valued at about $3,144,000. Finally, Kingdon Capital Management L.L.C. lifted its holdings in Jasper Therapeutics by 16.4% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock valued at $2,793,000 after acquiring an additional 500,000 shares during the period. 79.85% of the stock is owned by hedge funds and other institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.